文献速递妇科肿瘤

尼拉帕利个体化起始剂量用于铂敏感复发性卵巢癌维持治疗的III期NORA研究

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆.
PubMed 文献 · Ann Oncol · 2021-01-14

NORA研究是在中国30个中心开展的随机双盲安慰剂对照III期试验,纳入265例铂敏感复发性卵巢癌患者,按2:1随机接受尼拉帕利或安慰剂维持治疗,方案修订后采用个体化起始剂量。意向治疗人群中尼拉帕利组中位PFS为18.3个月,显著优于安慰剂的5.4个月(HR=0.32,P<0.0001)。个体化起始剂量下无论BRCA突变状态均观察到PFS获益,≥3级治疗出现不良事件发生率为50.8%对19.3%。

要点

  • 尼拉帕利维持治疗使铂敏感复发性卵巢癌疾病进展或死亡风险降低68%。
  • 意向治疗人群中位PFS为18.3个月对5.4个月(HR=0.32,95%CI 0.23-0.45)。
  • 个体化起始剂量(体重<77kg或血小板<150×10^3/μl者200mg/日)有效且安全。

核心结论

  • 尼拉帕利维持治疗较安慰剂显著延长铂敏感复发性卵巢癌患者的PFS,降低疾病进展或死亡风险68%。
  • 个体化起始剂量尼拉帕利有效且安全,应考虑作为该人群的标准实践。

研究设计与样本

  • III期随机双盲安慰剂对照研究,在中国30个中心开展(NCT03705156)。
  • 纳入对最近含铂化疗有应答的铂敏感复发性卵巢癌成人患者,按2:1随机接受口服尼拉帕利或匹配安慰剂直至疾病进展或不可接受毒性。
  • 方案修订后采用个体化起始剂量:体重<77kg或血小板<150×10^3/μl者200mg/日,其余300mg/日。
  • 随机分层因素为BRCA突变、倒数第二次化疗后复发时间及对最近化疗的应答。
  • 共265例患者随机(尼拉帕利177例,安慰剂88例),其中249例接受个体化起始剂量(300mg 14例,200mg 235例)。

主要发现

  • 意向治疗人群中位PFS尼拉帕利组18.3个月(95%CI 10.9-不可评估),安慰剂组5.4个月(95%CI 3.7-5.7),HR=0.32(95%CI 0.23-0.45),P<0.0001。
  • 接受个体化起始剂量的患者中,无论BRCA突变状态均观察到相似的PFS获益。
  • ≥3级治疗出现不良事件发生率尼拉帕利组50.8%,安慰剂组19.3%。
  • 最常见≥3级不良事件为中性粒细胞计数降低(20.3%对8.0%)和贫血(14.7%对2.3%)。

临床怎么用

  • 对含铂化疗应答的铂敏感复发性卵巢癌患者,可考虑尼拉帕利维持治疗。
  • 采用个体化起始剂量:体重<77kg或血小板<150×10^3/μl者200mg/日,其余300mg/日。
  • 治疗期间需监测中性粒细胞计数和贫血等血液学不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer. PATIENTS AND METHODS: In this phase III, double-blind, placebo-controlled study conducted at 30 centers in China, adults with platinum-sensitive recurrent ovarian cancer who had responded to their most recent platinum-containing chemotherapy were randomized 2 : 1 to receive oral niraparib (300 mg/day) or matched placebo until disease progression or unacceptable toxicity (NCT03705156). Following a protocol amendment, patients with a bodyweight <77 kg or a platelet count <150 × 103/μl received 200 mg/day, and all other patients 300 mg/day, as an individualized starting dose (ISD). Randomization was carried out by an interactive web response system and stratified by BRCA mutation, time to recurrence following penultimate chemotherapy, and response to most recent chemotherapy. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. RESULTS: Between 26 September 2017 and 2 February 2019, 265 patients were randomized to receive niraparib (n = 177) or placebo (n = 88); 249 patients received an ISD (300 mg, n = 14; 200 mg, n = 235) as per protocol. In the intention-to-treat population, median PFS was significantly longer for patients receiving niraparib versus placebo: 18.3 [95% confidence interval (CI), 10.9-not evaluable] versus 5.4 (95% CI, 3.7-5.7) months [hazard ratio (HR) = 0.32; 95% CI, 0.23-0.45; P < 0.0001], and a similar PFS benefit was observed in patients receiving an ISD, regardless of BRCA mutation status. Grade ≥3 treatment-emergent adverse events occurred in 50.8% and 19.3% of patients who received niraparib and placebo, respectively; the most common events were neutrophil count decreased (20.3% versus 8.0%) and anemia (14.7% versus 2.3%). CONCLUSIONS: Niraparib maintenance treatment reduced the risk of disease progression or death by 68% and prolonged PFS compared to placebo in patients with platinum-sensitive recurrent ovarian cancer. Individualized niraparib dosing is effective and safe and should be considered standard practice in this setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. Ann Oncol. 2021. PMID: 33453391. doi:10.1016/j.annonc.2020.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。